热门资讯> 正文

Pharvaris GAAP EPS of -€0.60

2025-11-12 22:42

Pharvaris N.V.(PHVS) 0
摩根士丹利(MS) 0

Pharvaris press release (PHVS): Q3 GAAP EPS of -€0.60.
Cash and cash equivalents were €329 million as of September 30, 2025, compared to €281 million for December 31, 2024.
Research and Development (R&D) Expenses. R&D expenses were €29.8 million for the quarter ended September 30, 2025, compared to €25.8 million for the quarter ended September 30, 2024.
General and Administrative (G&A) Expenses. G&A expenses were €9.8 million for the quarter ended September 30, 2025, compared to €12.1 million for the quarter ended September 30, 2024.

More on Pharvaris

Pharvaris N.V. (PHVS) Presents at ACAAI 2025 Annual Scientific Meeting - Slideshow
Pharvaris N.V. (PHVS) Presents at 2025 HAE International (HAEi) Regional Conference EMEA - Slideshow
Pharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Seeking Alpha’s Quant Rating on Pharvaris
Historical earnings data for Pharvaris

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。